Victoza® helps lower the risk of major cardiovascular events. Talk to your health care provider about how Victoza® not only lowers A1C, but also reduces the risk of major CV events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease.

Victoza® is a noninsulin diabetes medication used along with diet and exercise to improve blood sugar in adults and children 10 years of age and older with type 2 diabetes. Victoza® starts to lower blood sugar levels in as soon as 2 weeks, lowers A1C, and keeps it down.

Multiple mechanisms have been studied to explain the cardiovascular benefits of GLP-1 RAs. On one hand, GLP-1 RAs have been shown to effectively improve CV risk factors, including body weight, systolic blood pressure, LDL cholesterol and triglyceride concentrations, and glycemic control [16].

Effectiveness for type 2 diabetes Victoza has been found effective in improving blood sugar levels in adults and children with type 2 diabetes. For details on the effectiveness of Victoza, see the “Victoza uses” section below.

Yes, you can use Victoza at any time of the day or night. However, it may be best to use it at the same time of the day, once every day, so that you get into a routine.

In cardiovascular outcomes trials, glucagon-like peptide 1 receptor (GLP1R) agonists have been shown to reduce the rates of major adverse cardiovascular events (MACE), comprising non-fatal myocardial infarction, non-fatal stroke and cardiovascular death, in patients with type 2 diabetes mellitus.

Current guidelines recommend the following, presently available GLP-1 RA with proven CV benefit: liraglutide, semaglutide subcutaneously, and dulaglutide.

Victoza® works like the hormone glucagon-like peptide-1 (GLP-1) (7-37)a to:

• Slow food leaving your stomach.
• Help prevent your liver from making too much sugar.
• Help the pancreas produce more insulin when your blood sugar levels are high.

While not a weight-loss product, Victoza® may help adults lose some weight. In clinical studies of adults with type 2 diabetes, ranging from 26 to 52 weeks in length, many lost some weight. In a large study, when Victoza® was added to metformin, adults lost on average up to 6.2 pounds.

Victoza® lowers A1C Victoza® 1.8 mg taken alone or in combination with other diabetes medications lowered A1C in adults by 1.0% to 1.5%, on average, in medical studies. That's good to know, because even a 1% drop in A1C can be important in the management of type 2 diabetes.

The underlying mechanisms for increased HR remain to be fully elucidated, but may be related to a direct GLP-1 receptor effect on myocytes in the sinoatrial node of the human heart and/or stimulation of the sympathetic nervous system.

GLP-1 RAs should be used in patients without HF to reduce atherosclerotic events and prevent new-onset HF. GLP-1 RAs may be used in selected patients with HFpEF to reduce ASCVD but not to reduce HF hospitalizations or cardiovascular death.